SIMVASTATIN, A COMPETITIVE INHIBITOR OF HMG-COA REDUCTASE, LOWERS CHOLESTEROL SATURATION INDEX OF GALLBLADDER BILE
SIMVASTATIN, A COMPETITIVE INHIBITOR OF HMG-COA REDUCTASE, LOWERS CHOLESTEROL SATURATION INDEX OF GALLBLADDER BILE
复制标题
DOI：
10.1002/hep.1840080531
复制
发表时间：
1988-09-01
期刊：
影响因子：
13.5
通讯作者：
GEBHARD, RL
中科院分区：
文献类型：
--
作者：
DUANE, WC;HUNNINGHAKE, DB;GEBHARD, RL
我们测试了辛伐他汀（一种与甲维苷相关的HMG-CoA还原酶的竞争性抑制剂）可能改变胆囊胆汁胆固醇饱和度的可能性。10例IIa型或IIb型高胆固醇血症患者在每天服用20或40 mg辛伐他汀治疗7至13周之前和之后进行了胆汁取样。辛伐他汀组胆囊胆平均胆固醇饱和指数由1.01降至0.77 （p < 0.01）。这一发现强烈提示用HMG-CoA还原酶抑制剂治疗不会导致胆固醇结石的发生。事实上，这增加了这种抑制剂在未来治疗胆结石中发挥作用的可能性。
We tested the possibility that simvastatin, a competitive inhibitor of HMG-CoA reductase related to mevinolin, might alter cholesterol saturation of gallbladder bile. Ten patients with Type IIa or IIb hypercholesterolemia underwent bile sampling before, and again after, treatment with 20 or 40 mg per day simvastatin for 7 to 13 weeks. Mean cholesterol saturation index of gallbladder bile fell from 1.01 to 0.77 during simvastatin treatment (p < 0.01). This finding strongly suggest that treatment with HMG-CoA reductase inhibitors will not predispose to development of cholesterol gallstones. Indeed, it raises the possibility that such inhibitors might have a future role to play in treatment of gallstones.